If an additional ACE2 reduction occurs after the COVID-19 treatment, this might amplify the dysregulation of the detrimental effects of the angiotensin II and AT1 receptor axis [49]; see the chart presented in Figure 8. The gene discussed is ACE2; the disease is COVID-19.